Aligos Therapeutics Inc (ALGS)
20.04
+0.25
(+1.26%)
USD |
NASDAQ |
Nov 22, 16:00
20.16
+0.12
(+0.60%)
After-Hours: 20:00
Aligos Therapeutics Debt to Equity Ratio: 0.00 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Mar 2021
--
Maximum
Mar 2021
--
Average
--
Median
Mar 2021
Debt to Equity Ratio Benchmarks
| Haemonetics Corp | 1.394 |
| Pliant Therapeutics Inc | -- |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.9382 |
| IGC Pharma Inc | 0.0183 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 88.43M |
| Total Liabilities (Quarterly) | 38.33M |
| Shareholders Equity (Quarterly) | 50.10M |
| Current Ratio | 3.809 |